vTv Therapeutics Inc
VTVT14.580USD
+0.005+0.03%
종가 08/04, 16:00（ET）시세는 15분 지연됩니다
38.09M시가총액
손실P/E TTM
자세한 내용은 vTv Therapeutics Inc 회사
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.
회사 정보
종목 코드 VTVT
회사 이름vTv Therapeutics Inc
상장일Jul 30, 2015
CEOMr. Paul Jai Sekhri
직원 수23
유형Ordinary Share
회계 연도 종료Jul 30
주소3980 Premier Dr
도시HIGH POINT
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호27265
전화13368410300
웹사이트https://vtvtherapeutics.com/
종목 코드 VTVT
상장일Jul 30, 2015
CEOMr. Paul Jai Sekhri
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-82.80%
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
2.25K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
--
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Dr. Michael Tung, M.D.
Dr. Michael Tung, M.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
--
--
Dan Spiegelman
Dan Spiegelman
Director
Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-82.80%
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
2.25K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
--
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
수익 분석
FY2023
데이터 없음
지역별USD
이름
수익
비율
United States
0.00
0.00%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Fri, May 16
마지막 업데이트: Fri, May 16
주주
주주 유형
주주
주주
비율
MacAndrews & Forbes Holdings, Inc.
34.88%
Samsara BioCapital, LLC
7.90%
Fidelity Management & Research Company LLC
6.81%
Baker Bros. Advisors LP
3.72%
The Vanguard Group, Inc.
1.59%
Other
45.10%
주주
주주
비율
MacAndrews & Forbes Holdings, Inc.
34.88%
Samsara BioCapital, LLC
7.90%
Fidelity Management & Research Company LLC
6.81%
Baker Bros. Advisors LP
3.72%
The Vanguard Group, Inc.
1.59%
Other
45.10%
주주 유형
주주
비율
Holding Company
34.88%
Investment Advisor
8.96%
Venture Capital
7.90%
Hedge Fund
4.09%
Investment Advisor/Hedge Fund
1.09%
Individual Investor
0.72%
Other
42.35%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
54
1.51M
57.65%
-16.72K
2025Q1
53
1.53M
60.03%
+1.63K
2024Q4
55
1.51M
61.92%
-7.51K
2024Q3
55
1.49M
61.31%
+181.69K
2024Q2
53
1.29M
53.13%
+308.00
2024Q1
64
1.68M
72.07%
+129.32K
2023Q4
64
1.40M
68.78%
-52.49K
2023Q3
72
1.41M
69.35%
-49.61K
2023Q2
81
1.40M
81.32%
+323.67K
2023Q1
107
1.40M
81.41%
+294.71K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
MacAndrews & Forbes Holdings, Inc.
912.98K
34.88%
--
--
Apr 01, 2025
Samsara BioCapital, LLC
206.78K
7.9%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
178.20K
6.81%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
97.31K
3.72%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
41.56K
1.59%
--
--
Mar 31, 2025
Northern Trust Investments, Inc.
15.63K
0.6%
+15.63K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
12.64K
0.48%
+1.00K
+8.62%
Mar 31, 2025
Connective Capital Management, LLC
9.38K
0.36%
+9.38K
--
Mar 31, 2025
Sekhri (Paul Jai)
5.00K
0.19%
-24.06K
-82.80%
Apr 01, 2025
Northern Trust Global Investments
4.71K
0.18%
-194.00
-3.96%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
비율0.01%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
날짜
유형
비율
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
